Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of RAB001 for early glucocorticoid-induced nontraumatic osteonecrosis of the femoral head
CTR20244223Phase 2Active
- Sponsor
- Lab-Ray
- Start
- Dec 2024
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of LLP2A-alendronate in osteonecrosis of the hip, osteonecrosis, sponsored by Lab-Ray. Started Dec 2024; status: active.
02
Drugs
LLP2A-alendronate
03
Conditions
osteonecrosis of the hiposteonecrosis
Beyond the preview
Go deeper on CTR20244223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244223.